Bevacizumab beyond Progression for Newly Diagnosed Glioblastoma (BIOMARK): Phase II Safety, Efficacy and Biomarker Study.
bevacizumab
biomarker
glioblastoma
progression
temozolomide
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
10 Nov 2022
10 Nov 2022
Historique:
received:
29
09
2022
revised:
27
10
2022
accepted:
04
11
2022
entrez:
26
11
2022
pubmed:
27
11
2022
medline:
27
11
2022
Statut:
epublish
Résumé
We evaluated the efficacy and safety of bevacizumab beyond progression (BBP) in Japanese patients with newly diagnosed glioblastoma and explored predictors of response to bevacizumab. This phase II study evaluated a protocol-defined primary therapy by radiotherapy with concurrent and adjuvant temozolomide plus bevacizumab, followed by bevacizumab monotherapy, and secondary therapy (BBP: bevacizumab upon progression). Ninety patients received the protocol-defined primary therapy (BBP group,
Identifiants
pubmed: 36428615
pii: cancers14225522
doi: 10.3390/cancers14225522
pmc: PMC9688169
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Chugai Pharmaceutical Co. Ltd.
ID : N/A
Références
Neurooncol Pract. 2017 Sep;4(3):171-181
pubmed: 31386014
J Clin Oncol. 2009 Oct 1;27(28):4733-40
pubmed: 19720927
N Engl J Med. 2005 Mar 10;352(10):997-1003
pubmed: 15758010
Eur Cytokine Netw. 2009 Dec;20(4):158-63
pubmed: 20167554
Brain Tumor Res Treat. 2017 Apr;5(1):1-9
pubmed: 28516072
Bioinformatics. 2017 Aug 01;33(15):2266-2272
pubmed: 28379302
J Clin Oncol. 2009 Feb 10;27(5):740-5
pubmed: 19114704
Lancet Oncol. 2013 Jan;14(1):29-37
pubmed: 23168366
Cancer Res. 2017 May 1;77(9):2266-2278
pubmed: 28235764
Lancet Oncol. 2014 Oct;15(11):1269-78
pubmed: 25273342
Oncologist. 2019 Apr;24(4):521-528
pubmed: 30266892
Cancer Epidemiol Biomarkers Prev. 2014 Oct;23(10):1985-96
pubmed: 25053711
EMBO J. 2020 Aug 3;39(15):e103790
pubmed: 32567735
N Engl J Med. 2000 Nov 9;343(19):1350-4
pubmed: 11070098
Lancet Oncol. 2009 May;10(5):459-66
pubmed: 19269895
J Clin Oncol. 2015 Sep 1;33(25):2735-44
pubmed: 26124478
Oncol Rep. 2020 Jun;43(6):2083-2092
pubmed: 32236632
J Clin Oncol. 2013 Mar 20;31(9):1219-30
pubmed: 23401453
Neuropathol Appl Neurobiol. 2020 Feb;46(2):111-124
pubmed: 31179566
Acta Neuropathol Commun. 2016 Aug 08;4(1):79
pubmed: 27503138
Mod Pathol. 2019 Dec;32(12):1744-1750
pubmed: 31296931
N Engl J Med. 2014 Feb 20;370(8):699-708
pubmed: 24552317
Acta Neuropathol Commun. 2018 Dec 4;6(1):134
pubmed: 30514397
Oncotarget. 2016 Nov 29;7(48):78541-78556
pubmed: 27705944
Brain Tumor Pathol. 2016 Apr;33(2):129-36
pubmed: 26826105
Acta Neuropathol. 2018 Nov;136(5):805-810
pubmed: 30259105
J Exp Med. 2019 May 6;216(5):1071-1090
pubmed: 30948495
Cancer Cell. 2006 Mar;9(3):157-73
pubmed: 16530701
Jpn J Clin Oncol. 2012 Oct;42(10):887-95
pubmed: 22844129
Mol Neurobiol. 2020 May;57(5):2461-2478
pubmed: 32152825
J Neurooncol. 2016 Sep;129(3):487-494
pubmed: 27406589
Br J Cancer. 2012 Oct 23;107(9):1481-7
pubmed: 23037712
J Clin Oncol. 2010 Apr 10;28(11):1963-72
pubmed: 20231676
Cancers (Basel). 2019 Apr 03;11(4):
pubmed: 30987226
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Nucleic Acids Res. 2017 Feb 28;45(4):e22
pubmed: 27924034
N Engl J Med. 2014 Feb 20;370(8):709-22
pubmed: 24552318